The effect of κ-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons

Anesthesia and Analgesia

Volumn 109, Issue 2, 2009, Pages 632-640

  Su, Xin ^a   Castle, Neil A ^a   Antonio, Brett ^a   Roeloffs, Rosemarie ^a   Thomas, James B ^a   Krafte, Douglas S ^a   Chapman, Mark L ^a  

^a Icagen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BRL 52537; ICI 204488; KAPPA OPIATE RECEPTOR AGONIST; SODIUM CHANNEL; TETRODOTOXIN; UNCLASSIFIED DRUG; 1 (3,4 DICHLOROPHENYL)ACETYL 2 (1 PYRROLIDINYL)METHYLPIPERIDINE; 1-(3,4-DICHLOROPHENYL)ACETYL-2-(1-PYRROLIDINYL)METHYLPIPERIDINE; ANALGESIC AGENT; KAPPA OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENANTIOMER; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY NERVE CELL; SODIUM CURRENT; SPINAL GANGLION; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL CULTURE; CELL MEMBRANE POTENTIAL; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; PAIN ASSESSMENT; PATCH CLAMP; SENSORY RECEPTOR;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; CELLS, CULTURED; GANGLIA, SPINAL; MEMBRANE POTENTIALS; PAIN MEASUREMENT; PATCH-CLAMP TECHNIQUES; PIPERIDINES; PYRROLIDINES; RATS; RECEPTORS, OPIOID, KAPPA; SENSORY RECEPTOR CELLS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRODOTOXIN;

EID: 67849104733     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181a909a4     Document Type: Article

References (43)

1. Stein C, Millan MJ, Yassouridis A, Herz A. Antinociceptive effects of-κ- and-κ-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism. Eur J Pharmcol 1988;155:255-264
2. Keita H, Kayser V, Guilbaud G. Antinociceptive effect of a k-opioid receptor agonist that minimally crosses the blood-brain barrier (ICI 204448) in a rat model of mononeuropathy. Eur J Pharmacol 1995;277:275-280
3. Su X, Sengupta JN, Gebhart GF. Effects of opioids on mechanosensitive pelvic nerve afferent fibers innervating the urinary bladder of the rat. J Neurophysiol 1997;77:1566-1580
4. Su X, Sengupta JN, Gebhart GF. Effect of kappa opioid receptorselective agonists on responses of pelvic nerve afferents to noxious colorectal distension. J Neurophysiol 1997;78:1003-1012
5. Su X, Joshi SK, Kardos S, Gebhart GF. Sodium channel blocking actions of the-κ-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects. J Neurophysiol 2002;87:1271-1279
6. Mitolo-Chieppa D, Natale L, Marasciulo FL, De Salvatore G, Mitolo CI, Siro-Brigiani G, Renna G, De Salvia MA. Involvement of-κ-opioid receptors in peripheral response to nerve stimulation in-κ-opioid receptor knockout mice. Auton Autacoid Pharmacol 2002;22:233-239
7. Joshi SK, Gebhart GF. Non-opioid actions of U50,488 enantiomers contribute to their peripheral cutaneous antinociceptive effects. J Pharmacol Exp Ther 2003;305:919-924
8. Joshi SK, Lamb K, Bielefeldt K, Gebhart GF. Arylacetamide k-opioid receptor agonists produce a tonic- and use-dependent block of tetrodotoxin-sensitive and -resistant sodium currents in colon sensory neurons. J Pharmacol Exp Ther 2003;307:367-372
9. Porreca F, Lai J, Bian D, Wegert S, Ossipov MH, Eglen RM, Kassotakis L, Novakovic S, Rabert DK, Sangameswaran L, Hunter JC. A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci USA 1999;96:7640-7644
10. Laird JM, Souslova V, Wood JN, Cervero F. Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice. J Neurosci 2002;22:8352-8356 (Pubitemid 35387574)
11. Yoshimura N, Seki S, Novakovic SD, Tzoumaka E, Erickson VL, Erickson KA, Chancellor MB, de Groat WC. The involvement of the tetrodotoxin-resistant sodium channel Na (v) 1.8 (PN3/SNS) in a rat model of visceral pain. J Neurosci 2001;21:8690-8696
12. Gold MS, Weinreich D, Kim CS, Wang R, Treanor J, Porreca F, Lai J. Redistribution of Nav1.8 in uninjured axons enables neuropathic pain. J Neurosci 2003;23:158-166
13. Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr Opin Neurobiol 2003;13:291-297
14. Su X, Wachtel RE, Gebhart GF. Capsaicin sensitivity and voltage-gated sodium currents in colon sensory neurons from rat dorsal root ganglia. Am J Physiol 1999;277:G1180-8
15. Simonin F, Gaveriaux-Ruff C, Befort K, Matthes H, Lannes B, Micheletti G, Mattei MG, Charron G, Bloch B, Kieffer B. Kappaopioid receptor in humans: CDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci USA 1995;92:7006-7010
16. Ulens C, Daenens P, Tytgat J. The dual modulation of GIRK1/GIRK2 channels by opioid receptor ligands. Eur J Pharmacol 1999;385:239-245
17. Grudt TJ, Williams JT. Kappa-opioid receptors also increase potassium conductance. Proc Natl Acad Sci USA 1993;90:11429-11432
18. Rothman RB, France CP, Bykov V, De Costa BR, Jacobson AE, Woods JH, Rice KC. Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: Evidence for three κ receptor subtypes. Eur J Pharmacol 1989;167:345-353
19. Taub DD, Eisenstein TK, Geller EB, Adler MW, Rogers TJ. Immunomodulatory activity of mu- and kappa-selective opioid agonist. Proc Natl Acad Sci USA 1991;88:360-364
20. Alzheimer C, ten Bruggencate G. Nonopioid actions of the kappa-opioid receptor agonists, U 50488H and U 69593 on electrophysiologic properties of hippocampal CA3 neurons in vitro. J Pharmacol Exp Ther 1990;255:900-905
21. Pugsley MK, Saint DA, Walker MJ. An electrophysiological basis for the antiarrhythmic actions of the kappa-opioid receptor agonist U-50,488H. Eur J Pharmacol 1994;261:303-309
22. Wu G, Ringkamp M, Hartke TV, Murinson BB, Campbell JN, Griffin JW, Meyer RA. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J Neurosci 2001;21:RC140
23. Joshi SK, Mikusa JP, Hernandez G, Baker S, Shieh CC, Neelands T, Zhang XF, Niforatos W, Kage K, Han P, Krafte D, Faltynek C, Sullivan JP, Jarvis MF, Honore P. Involvement of the TTX-resistant sodium channel Nav1.8 in inflammatory and neuropathic pain, but not post-operative pain states. Pain 2006; 23:75-82
24. Dong XW, Goregoaker S, Engler H, Zhou X, Mark L, Crona J, Terry R, Hunter J, Priestley T. Small interfering RNA-mediated selective knockdown of Nav1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience 2007;146:812-821
25. Sabido-David C, Faravelli L, Salvati P. The therapeutic potential of Na+ and Ca2+ channel blockers in pain management. Exper Opin Invest Drugs 2004;13:1249-1261
26. Priest BT, Murphy BA, Lindia JA, Diaz C, Abbadie C, Ritter AM, Liberator P, Iyer LM, Kash SF, Kohler MG, Kaczorowski GJ, MacIntyre DE, Martin WJ. Contribution of the tetrodotoxinresistant voltage-gated sodium channel Nav1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci USA 2005;102:9382-9387
27. Amaya F, Wang H, Costigan M, Allchome AJ, Hatcher JP, Egerton J, Stean T, Morisset V, Grose D, Gunthorpe MJ, Chessell IP, Tate S, Green PJ, Woolf CJ. The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci 2006;26:12852-12860
28. Baker MD, Chandra SY, Ding Y, Waxman SG, Wood JN. GTP-induced tetrodotoxin-resistant Na+ current regulates excitability in mouse and rat small diameter sensory neurones. J Physiol 2003;548:373-382
29. Gold MS, Dastmalchi S, Levine JD. Co-expression of nociceptor properties in dorsal root ganglion neurons from the adult rat in vitro. Neuroscience 1996;71:265-275
30. Gold MS, Reichling DB, Shuster MJ, Levine JD. Hyperalgesic agents increase a tetrodotoxin-resistant Na1 current in nociceptors. Proc Natl Acad Sci USA 1996;93:1108-1112
31. Krafte DS, Bannon AW. Sodium channels and nociception: Recent concepts and therapeutic opportunities. Curr Opin Pharmacol 2008;8:50-56
32. Waxman SG, KIocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic but not in adult spinal sensory neurons, and is re-expressed following axotomy. J Neurophysiol 1994;72:466-470
33. Kim CH, Oh Y, Chung JM, Chung K. The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation. Mol Brain Res 2001;95:153-161
34. Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1. 7 sodium channels in a painful inherited neuropathy. J Neurosci 2004;24:8232-8236
35. Fertleman C, Baker M, Parker K, Moffatt S, Elmslie F, Abrahamsen B, Ostman J, Klugbauer N, Wood J, Gardiner R. SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron 2006;52:767-774
36. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Nav1.7 and human pain disorders. Trends Neurosci 2007;30:555-563
37. Choi JS, Dib-Hajj SD, Waxman SG. Differential slow inactivation and use-dependent inhibition of Nav1.8 channels contribute to distinct firing properties in IB4+ and IB4- DRG neurons. J Neurophysiol 2007;97:1258-1265
38. Idanpaan-Heikkila JJ, Kalso EA, Seppala T. Antinociceptive actions of dexmedetomidine and the kappa-opioid agonist U50,488H against noxious thermal, mechanical and inflammatory stimuli. J Pharmacol Exp Ther 1994;271:1306-1313
39. Courtney KR. Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther 1975;195:225-236
40. Wagner LE, Eaton M, Sabnis SS, Gingrich KJ. Meperidine and lidocaine block of recombinant voltage-dependent Na+ channels: Evidence that meperidine is a local anesthetic. Anesthesiol 1999;91:1481-1490
41. Kuo CC, Huang RC, Lou BS. Inhibition of Na+ current by diphenhydramine and other diphenyl compounds: Molecular determinants of selective binding to the inactivated channels. Mol Pharmcol 2000;57:135-143
42. Kort ME, Drizin I, Gregg RJ, Scanio MJ, Shi L, Gross MF, Atkinson RN, Johnson MS, Pacofsky GJ, Thomas JB, Carroll WA, Krambis MJ, Liu D, Shieh CC, Zhang X, Hernandez G, Mikusa JP, Zhong C, Joshi S, Honore P, Roeloffs R, Marsh KC, Murray BP, Liu J, Werness S, Faltynek CR, Krafte DS, Jarvis MF, Chapman ML, Marron BE. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J Med Chem 2008;51:407-416
43. Liu CN, Wall PD, Ben-Dor E, Michaelis M, Amir R, Devor M. Tactile allodynia in the absence of C-fiber activation: Altered firing properties of DRG neurons following spinal nerve injury. Pain 2000;85:503-521